Global Health has announced exciting news about their male sexual enhancement drug, X-Excite. GHLV has occupied Clinical Investigations Ltd. of United Kingdom to target the human clinical trials for X-Excite in Europe under the European Regulatory Guidelines (EMEA).
"We are very pleased that our product, X-Excite is now entering human clinical trials, a significant milestone in the development and progression of this drug. We now can move aggressively forward towards regulatory approval and eventual marketing of our drug, X-Excite," said Dr. Hassan Salari, Global Health President and CEO.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move.
Sign Up for our Free Stock Newsletter
About Global Health Ventures
The Company is a specialty pharma focused on the life style products. The Company is developing a new proprietary platform technology that delivers many approved drugs via the sublingual (under the tongue) route. This unique method delivers low dose drugs directly to the blood stream, bypassing all the side effects of digestive and liver system breakdowns, while maintaining product efficacy.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
